
Carlo Ferrari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/54003/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Involvement of non-coding RNAs and transcription factors in the induction of Transglutaminase isoforms by ATRA. Amino Acids, 2019, 51, 1273-1288.	1.2	7
2	Safety, efficacy and pharmacodynamics of vesatolimod (CS-9620) in virally suppressed patients with chronic hepatitis B. Journal of Hepatology, 2018, 68, 431-440.	1.8	147
3	<i>IL21R</i> expressing CD14 ⁺ CD16 ⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784.	1.7	36
4	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nature Medicine, 2017, 23, 327-336.	15.2	251
5	T cell regulation in HBV-related chronic liver disease. Journal of Hepatology, 2017, 66, 1096-1098.	1.8	14
6	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Digestive and Liver Disease, 2017, 49, 731-741.	0.4	19
7	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. Journal of Hepatology, 2017, 67, 543-548.	1.8	48
8	Modeling costâ€effectiveness and health gains of a "universal―versus "prioritized―hepatitis C virus treatment policy in a realâ€life cohort. Hepatology, 2017, 66, 1814-1825.	3.6	25
9	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
10	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. Journal of Medical Virology, 2016, 88, 843-851.	2.5	3
11	Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of Hepatology, 2016, 65, 509-516.	1.8	142
12	Adaptive immunity in HBV infection. Journal of Hepatology, 2016, 64, S71-S83.	1.8	358
13	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1–G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Annals of Surgical Oncology, 2016, 23, 981-989.	0.7	58
14	Missed treatment in an Italian HBV infected patients cohort: HBV RER. Digestive and Liver Disease, 2016, 48, 1346-1350.	0.4	2
15	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 2016, 48, 995-1005.	0.4	13
16	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. International Journal of Oncology, 2016, 48, 1280-1289.	1.4	10
17	Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. Oncolmmunology, 2016, 5, e1154249.	2.1	37
18	A method for measuring individual research productivity in hospitals: development and feasibility. BMC Health Services Research, 2015, 15, 468.	0.9	13

#	Article	IF	CITATIONS
19	Bariatric Surgery in Patients with Inflammatory Bowel Disease: An Accessible Path? Report of a Case Series and Review of the Literature. Journal of Crohn's and Colitis, 2015, 9, 185-190.	0.6	40
20	<scp>HBV</scp> and the immune response. Liver International, 2015, 35, 121-128.	1.9	153
21	Natural killer cell phenotype modulation and natural killer/Tâ€cell interplay in nucleos(t)ide analogueâ€treated hepatitis e antigenâ€negative patients with chronic hepatitis B. Hepatology, 2015, 62, 1697-1709.	3.6	73
22	The Role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cerebrospinal Fluids for Screening of Acute Bacterial Meningitis. Clinical Laboratory, 2014, 60, 377-81.	0.2	16
23	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. Journal of Hepatology, 2013, 59, 221-228.	1.8	34
24	Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. Clinica Chimica Acta, 2013, 418, 59-62.	0.5	17
25	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 1385-1395.	0.8	3
26	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 5465-5473.	3.2	46
27	Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgraduate Medical Journal, 2013, 89, 294-304.	0.9	49
28	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2013, 8, e56991.	1.1	12
29	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. Journal of Clinical Investigation, 2013, 123, 3766-3776.	3.9	80
30	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut, 2012, 61, 1076-1084.	6.1	51
31	Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut, 2012, 61, 1754-1764.	6.1	387
32	Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. Journal of Hepatology, 2012, 56, 1239-1246.	1.8	75
33	Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells. Gastroenterology, 2012, 143, 78-87.e3.	0.6	63
34	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. Gastroenterology, 2012, 143, 963-973.e9.	0.6	308
35	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. Gastroenterology, 2012, 143, 1576-1585.e4.	0.6	106
36	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e32493.	1.1	61

#	Article	IF	CITATIONS
37	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 2012, 12, 11.	0.8	30
38	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. Digestive and Liver Disease, 2011, 43, 259-265.	0.4	29
39	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. PLoS ONE, 2011, 6, e17232.	1.1	131
40	The Host–pathogen Interaction during HBV Infection: Immunological Controversies. Antiviral Therapy, 2010, 15, 15-24.	0.6	96
41	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology, 2010, 51, 1523-1530.	3.6	105
42	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
43	Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans. PLoS Pathogens, 2010, 6, e1001051.	2.1	72
44	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. Gastroenterology, 2010, 138, 682-693.e4.	0.6	416
45	Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. Gastroenterology, 2010, 138, 1931-1942.e2.	0.6	154
46	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. Gastroenterology, 2010, 138, 1536-1545.	0.6	162
47	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2009, 104, 605-616.	0.2	35
48	The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. Gastroenterology, 2008, 134, 1470-1481.	0.6	115
49	Therapeutic Vaccination for Hepatitis C: Can Protective T-Cell Responses Be Restored After Prolonged Antigen Exposure?. Gastroenterology, 2008, 134, 1601-1604.	0.6	7
50	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. Journal of Hepatology, 2008, 48, 548-558.	1.8	113
51	Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-î±2a/ribavirin therapy. Journal of Hepatology, 2008, 48, 932-938.	1.8	7
52	Corrigendum to "Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment―[J Hepatol 48 (2008) 548–558]. Journal of Hepatology, 2008, 49, 483.	1.8	0
53	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scandinavian Journal of Gastroenterology, 2008, 43, 73-80.	0.6	29
54	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. Journal of Virology, 2008, 82, 10986-10997.	1.5	114

#	Article	IF	CITATIONS
55	Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. Journal of Immunotherapy, 2008, 31, 271-282.	1.2	72
56	Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. Journal of Virology, 2007, 81, 4215-4225.	1.5	801
57	Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine, 2007, 25, 8585-8597.	1.7	160
58	T and B Cells in Hepatitis C Virus Control: What They Do and When They Fail. Gastroenterology, 2007, 132, 801-805.	0.6	6
59	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology, 2007, 133, 1132-1143.	0.6	57
60	Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology, 2007, 45, 258-259.	3.6	6
61	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology, 2007, 45, 588-601.	3.6	266
62	Impact of disease severity on outcome of antiviral therapy in treatment-naÃ ⁻ ve patients with chronic hepatitis C. Hepatology, 2007, 45, 1333-1334.	3.6	3
63	Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients. Gastroenterology, 2006, 130, 1098-1106.	0.6	87
64	New perspectives for T-cell-based HCV vaccines. Journal of Hepatology, 2006, 45, 163-165.	1.8	6
65	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology, 2006, 43, 602-611.	3.6	35
66	Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology, 2006, 44, 126-139.	3.6	176
67	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology, 2006, 44, 1617-1625.	3.6	193
68	Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFNâ€Î±2a and Ribavirin for Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2006, 194, 895-903.	1.9	201
69	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. Cancer Research, 2006, 66, 1139-1146.	0.4	236
70	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. Journal of Virology, 2006, 80, 11398-11403.	1.5	521
71	Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology, 2005, 41, 826-831.	3.6	57
72	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. Journal of Virology, 2005, 79, 7860-7867.	1.5	386

#	Article	IF	CITATIONS
73	The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. Journal of Immunology, 2005, 175, 7519-7529.	0.4	57
74	Heterologous T cell immunity in severe hepatitis C virus infection. Journal of Experimental Medicine, 2005, 201, 675-680.	4.2	134
75	Is Steroid Therapy Needed in the Treatment of Destructive Thyrotoxicosis Induced by α-Interferon in Chronic Hepatitis C?. Hormone Research in Paediatrics, 2005, 63, 194-199.	0.8	10
76	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 250-257.	1.8	143
77	Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection. European Journal of Immunology, 2004, 34, 3208-3215.	1.6	14
78	Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. Hepatology, 2004, 40, 289-299.	3.6	13
79	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. Journal of Hepatology, 2004, 40, 102-109.	1.8	66
80	Kinetics of the immune response during HBV and HCV infection. Hepatology, 2003, 38, 4-13.	3.6	227
81	Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. Journal of Hepatology, 2003, 39, 595-605.	1.8	229
82	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. Journal of Virology, 2002, 76, 12423-12434.	1.5	168
83	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel. Aids, 2002, 16, 813-828.	1.0	280
84	Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: Functional characterization in patients with chronic hepatitis C. Hepatology, 2002, 35, 1225-1236.	3.6	68
85	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology, 2002, 36, 1446-1452.	3.6	66
86	Comparative pathogenesis of HBV and HCV. Virus Research, 2001, 82, 19-23.	1.1	5
87	Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology, 2001, 33, 1533-1543.	3.6	40
88	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. Journal of Experimental Medicine, 2000, 191, 1269-1280.	4.2	761
89	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. Hepatology, 1999, 30, 1088-1098.	3.6	150
90	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology, 1999, 117, 1386-1396.	0.6	331

#	Article	IF	CITATIONS
91	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. Seminars in Virology, 1996, 7, 23-30.	4.1	8
92	The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response. Nature Medicine, 1996, 2, 1104-1108.	15.2	804
93	Hepatitis B virus immunopathology. Seminars in Immunopathology, 1995, 17, 261-81.	4.0	120
94	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology, 1994, 19, 286-295.	3.6	238
95	Hepatitis C virus viremia following clinical resolution of acute hepatitis C. Journal of Hepatology, 1994, 20, 666-671.	1.8	49
96	PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. Journal of Hepatology, 1994, 20, 47-56.	1.8	8
97	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology, 1994, 19, 286-295.	3.6	21
98	Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology, 1992, 103, 255-263.	0.6	50
99	Longâ€term followâ€up of antiâ€hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. Liver, 1992, 12, 94-99.	0.1	17
100	The cellular immune response to nucleocapsid antigens in hepatitis B virus infection. Seminars in Immunopathology, 1990, 12, 25-31.	4.0	10
101	Hepatitis B virus structure and biology. Microbial Pathogenesis, 1989, 6, 311-325.	1.3	78
102	Evaluation of monoclonality of cell lines from sequential dilution assays. Journal of Immunological Methods, 1987, 105, 139-143.	0.6	13